Information Provided By: 
Fly News Breaks for May 23, 2018
SNY, REGN
May 23, 2018 | 06:52 EDT
Barclays analyst Geoff Meacham says his analysis suggests Eylea concentration remains a big risk for Regeneron Pharmaceuticals (REGN). A scenario analysis shows the company's adjusted earnings is sensitive to even modest changes to U.S. Eylea sales versus any product under the Sanofi (SNY) joint venture, namely Dupixent, Praluent, and Kevzara, Meacham tells investors in a research note. The analyst reiterates an Underweight rating on Regeneron with a $290 price target.
News For REGN;SNY From the Last 2 Days
